A study of serum uric acid and atrial fibrillation in hypertensive patients

Chinky Sharma; Harekrishna Sharma; Vasundhara Sharma; Ratish Raman

doi:10.53730/ijhs.v6nS5.9372

Authors

Chinky Sharma Assistant Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre, Moradabad, Uttar Pradesh, India
Harekrishna Sharma
harshshrm@yahoo.com
Associate Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre, Moradabad, Uttar Pradesh, India
Vasundhara Sharma Associate Professor, Department of Microbiology, Teerthanker Mahaveer Medical College & Research Centre, Moradabad, Uttar Pradesh, India
Ratish Raman Assistant Professor, Department of Radiology, Teerthanker Mahaveer Medical College & Research Centre, Moradabad, Uttar Pradesh, India

Keywords:

Uric Acid, Atrial Fibrillation, Hypertension

Abstract

Background: The aim is to study the correlation of serum uric acid and atrial fibrillation in hypertensive individuals and the effect of duration of hypertension on atrial fibrillation & serum uric acid (SUA). Materials and Methods: Patients (age between 35-65years) were selected from outpatient OPD & IPD. A control group of 100 non hypertensive individuals and another group of 100 hypertensive patients were enrolled. Serum uric acid, Echocardiography: A Trans Thoracic Echocardiography (TTE) measurement of Left atrium diameter (LVST), interventricular septal thickness (LVPWT), posterior wall thickness, left ventricular end diastolic diameter (LV) and LV ejection fraction (LVEF) was recorded. Results: Hyperuricemia incidence in controls was 11% and hyperuricemia incidence in cases was 65 %. The incidence of hyperuricemia in cases with phase 1 of hypertension was 6.27±1.22 mg/dl and those with phase 2 of hypertension was 7.59±1mg/dl which was significant. Atrial fibrillation incidence was 4% in the hypertensive patients and the atrial fibrillation incidence in normotensive patients was 1%. Conclusion: Hypertension duration had a significant effect on the SUA levels and revealed that there was noteworthy increase in the SUA level in individuals with atrial fibrillation than those without atrial fibrillation.

Downloads

Download data is not yet available.

References

Huchard H. Arteriosclerosis. Including its cardiac form. JAMA 1909;53:1129-32.

Gertler MM, Garn SM and Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951;34:1421-31.

Brand FN, Mcge DL, Kannel WB, Stokes J and Castelli WP. Hyperuricemia as a risk factor of coronary heart disease. The Framingham Study. Am J Epidemiol. 1985;121:11-8.

Cannon PJ, Stason Wb, Demartini FE, Sommers SC and laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-64.

Kinsey D, Walther R, Sise HS, Whitelaw G and Smithwick R. Incidence of hyperuricemia in 400 hypertenssive subjects. Circulation 1961;24:972-3.

Curtis JJ, Luke RG, Jones P and Diethelm AG. Hypertension in cyclosporin treated renal transplant recipients in sodium dependent. Am J Med 1988:85;134-8.

Diniari, N. K. S., & Aryani, L. N. A. (2022). Characteristics and pharmacological treatment options of delirium patients treated at Sanglah Central General Hospital . International Journal of Health & Medical Sciences, 5(1), 37-43. https://doi.org/10.21744/ijhms.v5n1.1835

Ciaroni S, Cuenoud L and Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 2000;139: 814–9.

Rosamond W. Heart disease and stroke statistics—2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation. 2008;117(4):25–146.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Lloyd-Jones DM, Wang TJ and Leip EP. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–6.

Bulpitt C.J. Serum Uric Acid in hypertensive patients British Heart Journal 1975, 37; 1210-15.

Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH and Aristimuno GG. Serum Uric Acid in Essential Hypertension: an indicator of renal vascular involvement. Annuls of Internal Medicine 1980; 93:817-21.

Tykarski A. Evaluation of renal handling of uric acid in essential hypertension; hyperuricemia related to decreased urate secretion Nephrology 1991, 59(3); 364-68.

Kannel WB, Abbott RD, Savage DD and McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306: 1018–102.

Krahn AD, Manfreda J, Tate RB, Mathewson FA and Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. AmJ Med1995;s98: 476–84.